Rituximab vs placebo
Participant subjective impression of change stable or improved at 8 to 12 months · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
Rituximab may leads to higher participant subjective impression of change stable or improved at 8… compared with placebo (low certainty).
1 finding from 1 review
- Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes onlyRR 1.86 [1.27, 2.71]2 studies · 70 participantsLow